Investigators examined adult patients who had undergone allogeneic stem cell transplantation (alloSCT) and developed both BK polyomavirus reactivation (BKPyV viruria) and skin graft-versus-host disease (GvHD). The cohort came from two recruitment streams: seven patients (58.3% of the sample) identified during a prospective inpatient trial focused on urological complications after alloSCT, all of whom presented with acute skin GvHD; and five patients (41.7%) recruited from a prospective long-term survivor study, each more than five years post-transplant and examined while manifesting chronic skin GvHD. Acute myeloid leukemia was the most frequent underlying indication for transplantation (n=7), followed by Non-Hodgkin lymphoma (n=2). The source did not report additional demographic details such as age distribution, conditioning regimens, donor types, or immunosuppressive treatments.
The study design was an immunohistochemical pilot investigation. The authors reported prospective registration in the German Clinical Trials Register under DRKS00039127 and noted that the full protocol is available via the registry. The source did not include sample-size justifications, power calculations, or expanded inclusion/exclusion criteria in the abstract, so those details must be sought in the registry or full protocol if required for interpretation.
The primary laboratory endpoint was detection of BKPyV structural and regulatory proteins—LTAg (large T antigen) and VP1—in skin biopsy specimens by immunohistochemistry. Investigators reported that IHC staining was negative for both LTAg and VP1 in all examined patients. This absence of detectable viral protein signal applied across the acute GvHD cases and the chronic GvHD long-term survivors alike. Because both viral proteins were negative by IHC in every specimen, the study team stated that they did not proceed to further molecular investigations within this pilot.
The authors interpreted these IHC findings as showing no evidence of an association between expression of BKPyV proteins LTAg or VP1 and histologically assessed skin GvHD in their sample. The source text emphasized that the negative IHC results were consistent across the cohort; it did not, however, present quantitative metrics for staining intensity, reporting thresholds, or controls in the abstract. Those technical details are not reported in the abstract and would need to be referenced in the full protocol or methods section.
The investigation was prospectively registered at the German Clinical Trials Register (DRKS00039127). The authors confirmed ethical approval from the local ethics review board at the University Medical Center Greifswald (approval BB 264/25 from December 21, 2025) and stated that all relevant patient consent and oversight procedures were followed. Data produced in the study are available upon reasonable request to the authors, according to the source.
The manuscript appears on medRxiv as a preprint and has not undergone peer review. The authors explicitly stated no competing interests. Because this is a preprint, the IHC findings have not been certified by external review, and the source cautions against using the results to guide clinical practice without further validation.
The authors framed the project as a pilot study and urged caution in interpreting the findings. The source declared negative IHC results for both LTAg and VP1, and that no additional molecular assays were performed after those negative results. The abstract does not provide details on several potentially relevant elements: the number of biopsies per patient, the specific IHC antibodies and controls used, limits of detection for the assays, or whether viral DNA/RNA testing was considered or attempted. Those methodological gaps limit the degree to which one can generalize from the reported negative protein staining.
Investigators did not report demographic covariates or transplant-related variables in detail within the abstract—factors such as conditioning intensity, donor source, immunosuppression regimen, timing of BKPyV detection relative to GvHD onset, and concurrent infections could all influence interpretation. The source did not include statistical analyses, power calculations, or prespecified molecular follow-up plans in the abstract. Because the authors stopped further molecular work after negative IHC findings, the question of whether BKPyV nucleic acids or nonstructural markers might be present despite absent protein expression remains open.
Readers should treat these results as preliminary. The study provides a defined clinical observation—no IHC-detected LTAg or VP1 in the sampled skin GvHD lesions among this small, registered cohort—but does not eliminate other forms of BKPyV involvement that were not assessed. Future work, as implied by the pilot framing, would require larger cohorts, detailed reporting of IHC assay characteristics, and complementary molecular testing to resolve whether BKPyV contributes to skin pathology in the alloSCT population.
Study limitations, next regulatory or research milestones, and specific unanswered laboratory questions are documented in the original source and should guide follow-up investigations rather than immediate changes to clinical care.